Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Investigating KAT2A protac therapy for targeting leukemic blast differentiation in acute myeloid leukaemia.

View Full Paper
Ask AI
Bookmark
Share

Authors

SWSimon E. Ward

Discussion

Loading...

Member takes

Overview

Investigating the effects of KAT2A-targeting therapy on differentiation and survival outcomes in leukaemia cells, indicating therapeutic potential.

Key Points

  • KAT2A-targeting therapy demonstrated significant differentiation effects in AML cells while reducing cell growth by targeting blast populations.
  • Average potency was confirmed at 33nM in sensitive primary AML patient samples, supporting potential clinical applicability.
  • Initial assessments utilized multiple AML cell lines and primary samples focusing on KAT2A degradation and differentiation mechanisms.
  • Drug efficacy was sustained in stromal cultures, highlighting potential for combination with established agents like Cytarabine and Venetoclax.

Cite This Study

Simon E. Ward (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dcf1https://doi.org/10.1182/blood-2025-1504
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Rapid proteasomal degradation of mutant feline McDonough sarcoma-like tyrosine kinase-3 overcomes inhibitor resistance mechanisms of acute myeloid leukemia cells2025
  2. 2Amx-883, a potent and selective degrader of BRD9 drives differentiation in acute myeloid leukaemia and shows synergistic efficacy in combination with venetoclax In Vivo and prevents the emergence of resistance to venetoclax in vitro.2025 · 1 citations
  3. 3HDAC inhibitors potentiate the efficacy of antineoplastic agents in acute megakaryoblastic leukemia via dual activation of apoptosis and pyroptosis2025
  4. 4A first-in-class oral clinical candidate targeting MLLT1 and 3 degradation for the treatment of advanced AML and ALL including menin inhibitor resistant / refractory disease2025
  5. 5Synergistic targeting of KMT2A-rearranged AML with combined LSD1 and menin inhibitors2025